CIK 0001615219 · Non-accelerated filer<br>Smaller reporting company
Decoy Therapeutics Inc.
Sign in to watch- Ticker
- DCOY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465087339
- Phone
- 346-772-0346
- Business address
- 2450 HOLCOMBE BLVD, SUITE J-608, HOUSTON, TX, 77021
- Former names
- Salarius Pharmaceuticals, Inc., Flex Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-08-19 | Arthur David J. Chief Executive Officer | Purchase | +1,000 | $1.01 | $1K | 2,000 |
| 2020-08-17 | Rosenblum Mark J Exec VP Finance, CFO | Purchase | +5,000 | $1.00 | $5K | 12,000 |
| 2020-07-14 | Arthur David J. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +339,584 | 339,584 | ||
| 2020-07-14 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award · Stock Option (right to buy) | +49,955 | 49,955 | ||
| 2020-07-14 | Lieber Jonathan I Director | Grant or award · Stock Option (right to buy) | +3,000 | 3,000 | ||
| 2020-03-23 | Northrup Jonathan P Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2020-03-23 | McVicar William K. Director | Grant or award · Common Stock | +6,000 | 6,000 | ||
| 2020-03-23 | McCreedy Bruce J Jr. Director | Grant or award · Common Stock | +6,000 | 6,000 | ||
| 2020-03-23 | Burleson Tess Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2020-03-23 | Rosenblum Mark J Exec VP Finance, CFO | Grant or award · Common Stock | +30,000 | 30,000 | ||
| 2020-03-23 | HANISH ARNOLD C Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2020-03-23 | Arthur David J. Chief Executive Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2020-03-23 | Lammers Paul Director | Grant or award · Stock Option (right to buy) | +6,000 | 6,000 | ||
| 2020-02-19 | Rosenblum Mark J Exec VP Finance, CFO | Purchase | +2,000 | $0.95 | $2K | 7,000 |
| 2020-02-18 | Jordan Scott Chief Business Officer | Purchase | +11,300 | $0.90 | $10K | 31,609 |
| 2020-02-13 | Rosenblum Mark J Exec VP Finance, CFO | Purchase | +5,000 | $0.86 | $4K | 5,000 |
| 2020-02-11 | HANISH ARNOLD C Director | Purchase | +4,350 | $1.15 | $5K | 7,350 |
| 2020-02-11 | Arthur David J. Chief Executive Officer | Purchase · Warrants (right to buy) | +2,175 | $0.01 | $22 | 2,175 |
| 2020-02-11 | Northrup Jonathan P Director | Purchase · Warrants (right to buy) | +8,700 | $0.01 | $87 | 8,700 |
| 2020-02-11 | Burleson Tess Director | Purchase · Warrants (right to buy) | +4,350 | $0.01 | $44 | 4,350 |
Page 5 of 6 · 107 trades